PE20010628A1 - Compuestos de amina ciclica, su produccion y su uso - Google Patents

Compuestos de amina ciclica, su produccion y su uso

Info

Publication number
PE20010628A1
PE20010628A1 PE2000001025A PE0010252000A PE20010628A1 PE 20010628 A1 PE20010628 A1 PE 20010628A1 PE 2000001025 A PE2000001025 A PE 2000001025A PE 0010252000 A PE0010252000 A PE 0010252000A PE 20010628 A1 PE20010628 A1 PE 20010628A1
Authority
PE
Peru
Prior art keywords
hydrocarbon
divudina
heterocycle
link
methylsulfonil
Prior art date
Application number
PE2000001025A
Other languages
English (en)
Inventor
Shinichi Imamura
Shohei Hashiguchi
Taeko Hattori
Osamu Nishimura
Naoyuki Kanzaki
Masanori Baba
Yshihiro Sugihara
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26554466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PE20010628A1 publication Critical patent/PE20010628A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems

Abstract

SE REFIERE A UNA AMINA CICLICA DE FORMULA I; R1 ES H, HIDROCARBURO SUSTITUIDO POR UN HETEROCICLO; R2 ES UN HIDROCARBURO SUSTITUIDO POR UN HETEROCICLO O R1 Y R2 JUNTO CON A FORMAN UN HETEROCICLO; A ES N, N(+)(-R5).Y(-); R5 ES UN HIDROCARBURO; Y ES UN CONTRAANION; R3 ES UN HIDROCARBURO CICLICO, HETEROCICLO; n ES 0-1; R4 ES H, HIDROCARBURO, HETEROCICLO, ALCOXI, ARILOXI, AMINO; E ES UN HIDROCARBURO ALIFATICO DIVALENTE; G1 ES UN ENLACE, CO, SO2; G2 ES CO, SO2, NHCO, CONH, OCO; J ES METINA, N; Q Y R SON UN ENLACE, HIDROCARBURO ALIFATICO C1-C3; J ES METINA, CUANDO G2 ES OCO; UNO DE Q Y R ES UN ENLACE. SON COMPUESTOS PREFERIDOS N-(3,4-DICLOROFENIL)-1-(METILSULFONIL)-N-{3-[4-({4-[(METILSULFONIL)AMINO]FENIL}SULFONIL)-1-PIPERINIL]PROPIL}-4-PIPERIDINCARBOXAMIDA; N-(3-CLOROFENIL)-1-(METILSULFONIL)-N-(3-{4-[4-(METILSULFONIL)BENCIL]-1-PIPERIDINIL}PROPIL)-4-PIPERINCARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN INHIBIDOR DE PROTEASA COMO SAQUINAVIR, RITONAVIR, INDINAVIR, AMPRENAVIR, ENTRE OTROS, UN INHIBIDOR DE TRANSCRIPTASA INVERSA COMO ZIDOVUDINA, DIDANOSINA, ZALCITABINA, LAMIVUDINA, ABACAVIR, ENTRE OTROS Y A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR DE QUIMIOCINA, CCR5 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA ENFERMEDAD INFECCIOSA POR VIH
PE2000001025A 1999-10-01 2000-09-28 Compuestos de amina ciclica, su produccion y su uso PE20010628A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28208899 1999-10-01
JP2000046749 2000-02-18

Publications (1)

Publication Number Publication Date
PE20010628A1 true PE20010628A1 (es) 2001-06-18

Family

ID=26554466

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001025A PE20010628A1 (es) 1999-10-01 2000-09-28 Compuestos de amina ciclica, su produccion y su uso

Country Status (23)

Country Link
US (2) US6562978B1 (es)
EP (2) EP1220842B1 (es)
JP (2) JP3814136B2 (es)
KR (1) KR20020060190A (es)
CN (1) CN1390201A (es)
AR (1) AR025884A1 (es)
AT (1) ATE400555T1 (es)
AU (1) AU7448700A (es)
BR (1) BRPI0014428B8 (es)
CA (2) CA2608807A1 (es)
CO (1) CO5380013A1 (es)
CY (1) CY1108403T1 (es)
DE (1) DE60039446D1 (es)
DK (1) DK1220842T3 (es)
ES (1) ES2310173T3 (es)
HK (1) HK1046905A1 (es)
HU (1) HUP0300138A3 (es)
NO (1) NO20021450L (es)
PE (1) PE20010628A1 (es)
PL (1) PL203984B1 (es)
PT (1) PT1220842E (es)
WO (1) WO2001025200A1 (es)
ZA (1) ZA200202593B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AU2001288110A1 (en) * 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
WO2002051414A1 (fr) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Compositions médicinales s'administrant par voie orale
KR20030069218A (ko) * 2001-01-18 2003-08-25 다케다 야쿠힌 고교 가부시키가이샤 벤질피페리딘 화합물의 제조 방법
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
WO2002088089A1 (fr) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
US20050154016A1 (en) * 2002-04-19 2005-07-14 Katsunori Takashima Preventives for hiv infection
WO2003090748A1 (fr) * 2002-04-24 2003-11-06 Takeda Pharmaceutical Compay Limited. Utilisation de composes a antagonisme anti-ccr
WO2004026833A1 (ja) * 2002-09-20 2004-04-01 Takeda Pharmaceutical Company Limited 環状アミン化合物、その製造法および用途
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US20060019977A1 (en) * 2002-10-18 2006-01-26 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient
AU2003290323A1 (en) * 2002-12-24 2004-07-22 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
WO2005059107A2 (en) 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
SE0403084D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
BRPI0519288A2 (pt) 2004-12-24 2009-01-06 Astrazeneca Ab compostos heterocÍclicos como antagonistas de ccr2b
MX2007007553A (es) * 2004-12-24 2007-08-15 Prosidion Ltd Agonistas del receptor acoplado a proteina g (gpr116) y uso de los mismos para tratar obesidad y diabetes.
WO2006130426A2 (en) * 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
EP2465850B1 (en) 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8937181B2 (en) * 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
WO2008030853A2 (en) * 2006-09-06 2008-03-13 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2008073450A2 (en) * 2006-12-12 2008-06-19 Georgetown University Benzamide compounds
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
AU2008293542B9 (en) 2007-08-27 2014-08-07 Dart Neuroscience (Cayman) Ltd. Therapeutic isoxazole compounds
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CA2700974A1 (en) 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. Substituted aryl sulfone derivatives as calcium channel blockers
JP5846527B2 (ja) * 2010-02-17 2016-01-20 国立大学法人京都大学 TGF−βシグナル伝達阻害剤
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
KR20130025899A (ko) 2010-04-02 2013-03-12 피비코-1 엘엘씨 Ccr5 길항제,hiv―1 프로테아제 억제제 및 약동학적 인핸서를 포함하는 병용 요법
CN101921224B (zh) * 2010-05-21 2012-01-18 中国人民解放军军事医学科学院生物工程研究所 1-(3-氨基丙基)哌嗪-4-氨基酰胺类化合物及其制备方法与应用
KR200453948Y1 (ko) * 2011-02-28 2011-06-09 최문희 파마로드
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN103130709B (zh) * 2011-11-22 2017-04-12 常州亚邦制药有限公司 具有抗hiv活性的3‑氨基丙酸哌啶酰胺类化合物,合成方法及用途
TWI519515B (zh) 2011-12-21 2016-02-01 諾維拉治療公司 B型肝炎抗病毒劑
BR112015004192B1 (pt) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoíl-arilamidas, composição farmacêutica que os compreende e uso das mesmas no tratamento da hepatite b
DK2961732T3 (en) 2013-02-28 2017-07-10 Janssen Sciences Ireland Uc SULFAMOYLARYLAMIDS AND USE THEREOF AS MEDICINES TO TREAT HEPATITIS B
BR112015025052A2 (pt) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc derivados de n-fenil-carboxamida e o seu uso como medicamentos para o tratamento da hepatite b
ES2695182T3 (es) 2013-05-17 2019-01-02 Janssen Sciences Ireland Uc Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
NZ717629A (en) * 2013-10-23 2021-12-24 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
ES2792848T3 (es) 2014-02-05 2020-11-12 Novira Therapeutics Inc Politerapia para el tratamiento de infecciones por VHB
CA2932551A1 (en) 2014-02-06 2015-08-13 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
PL3641769T3 (pl) 2017-06-20 2022-09-26 Imbria Pharmaceuticals, Inc. Pochodna 1-[(2,3,4-trimetoksyfenylo)metylo]piperazyny, jej kompozycje oraz sposoby zwiększania wydajności metabolizmu serca
WO2019175657A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US20220363639A1 (en) * 2018-07-31 2022-11-17 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療hbv感染或hbv誘發的疾病之醯胺衍生物
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
CN117098560A (zh) * 2021-04-23 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗病毒多肽化合物
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2023107547A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Azetidine and spiroazetidine compounds and uses thereof
WO2023243601A1 (ja) * 2022-06-13 2023-12-21 モジュラス株式会社 アザシクロアルキルカルボニル環状アミン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203988A (en) * 1975-11-12 1980-05-20 Merck & Co., Inc. Pyridinyl ureas and pharmaceutical use
JPH0680054B2 (ja) * 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
PT693070E (pt) 1993-04-05 2002-12-31 Pharmaceutical Discovery Corp Pirido(2,3-b)(1,4)benzodiazepinonas como ligando do receptor m2 para o tratamento de desordens neurologicas
WO1999004794A1 (en) 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
KR20030069218A (ko) * 2001-01-18 2003-08-25 다케다 야쿠힌 고교 가부시키가이샤 벤질피페리딘 화합물의 제조 방법

Also Published As

Publication number Publication date
NO20021450D0 (no) 2002-03-22
US7348324B2 (en) 2008-03-25
PT1220842E (pt) 2008-10-17
JP2001302633A (ja) 2001-10-31
WO2001025200A1 (en) 2001-04-12
DK1220842T3 (da) 2008-11-10
JP2003048880A (ja) 2003-02-21
EP1220842B1 (en) 2008-07-09
ZA200202593B (en) 2003-04-03
HK1046905A1 (en) 2003-01-30
DE60039446D1 (de) 2008-08-21
ATE400555T1 (de) 2008-07-15
HUP0300138A3 (en) 2003-06-30
CA2385938A1 (en) 2001-04-12
EP1886994A1 (en) 2008-02-13
BR0014428A (pt) 2002-06-11
BRPI0014428B1 (pt) 2016-08-02
CN1390201A (zh) 2003-01-08
PL356034A1 (en) 2004-06-14
ES2310173T3 (es) 2009-01-01
EP1220842A1 (en) 2002-07-10
PL203984B1 (pl) 2009-11-30
CY1108403T1 (el) 2014-02-12
KR20020060190A (ko) 2002-07-16
BRPI0014428B8 (pt) 2021-05-25
AR025884A1 (es) 2002-12-18
NO20021450L (no) 2002-06-03
HUP0300138A2 (en) 2003-05-28
CA2608807A1 (en) 2001-04-12
US20030114443A1 (en) 2003-06-19
CO5380013A1 (es) 2004-03-31
CA2385938C (en) 2010-02-16
US6562978B1 (en) 2003-05-13
AU7448700A (en) 2001-05-10
JP3814136B2 (ja) 2006-08-23

Similar Documents

Publication Publication Date Title
PE20010628A1 (es) Compuestos de amina ciclica, su produccion y su uso
PE20040780A1 (es) Compuestos heterociclicos como antagonista de cgrp y procedimiento para su preparacion
ES2572980T3 (es) Combinación de inhibidores de la proteasa del VHC con un tensioactivo
PE20060323A1 (es) Oxadiazolonas y procedimientos para su preparacion
PE20091567A1 (es) Derivados de metastina en el tratamiento del cancer
PE20040892A1 (es) Antagonistas del receptor muscarinico m3 de acetilcolina
PE20060076A1 (es) Antagonistas del receptor de acetilcolina muscarinico
PE20040120A1 (es) Derivados de quinolina como antagonistas de npy
DE3850203D1 (de) Benzimidazolin-2-oxo-1-carboxylsäure-Derivate, verwendbar als Antagonisten von 5-HT-Rezeptoren.
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
PE20070355A1 (es) Antagonistas de cgrp seleccionados y procedimientos para su preparacion
UY29389A1 (es) Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones.
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
CR8595A (es) Inhibidor del dipeptidil-peptidasa
AR047898A1 (es) Benzamidas sustituidas,metodos de preparacion,composiciones farmaceuticas que las contienen y usos
BR0312811A (pt) Monoetano sulfonato de 3-z-[1-(4-(n-((4-metil piperazin-1-il) metil carbonil)-n-metil-amino) anilino)-1-fenil-metileno]-6-metóxi carbonil-2-indolinona e seu uso com uma composição farmacêutica
PE20060620A1 (es) Analogos de biaril piperazinil-piridina sustituidos como moduladores del receptor de capsaicina vr1
PE20090434A1 (es) Derivados de sulfonil amida como inhibidores de quinasas
PE20090595A1 (es) Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
AR040626A1 (es) Derivados de quinolina utiles como ligandos del receptor del neuropeptido y (npy)
PE20051036A1 (es) Antagonistas del receptor peptido relacionado con el gen de calcitonina
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4

Legal Events

Date Code Title Description
FX Voluntary withdrawal